VIPR1 and neoplasm: Furthermore, since rechallenging the tumor free mice resulted in complete tumor rejection in mice that received the combination of VIP-R antagonist and anti-PD-1, it further emphasized the role of the enhanced adaptive and long-lasting anti-tumor immunity generated in response to inhibiting VIP-R signaling.